In another phase II trial [49] vandetanib showed moderate activity in pretreated patients with NSCLC harboring RET rearrangements (ORR 18%, DCR 65%) and dose reduction was necessary in 4 of 18 (22%) patients enrolled. This evidence concerns the gene RET and non-small cell lung carcinoma.